ArticleCureus2026
Myeloid Sarcoma Arising in a Rare Anatomical Location: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid sarcoma (MS) is a rare extramedullary tumor of immature myeloid cells that can occur concurrently with acute myeloid leukemia (AML), precede its onset, or present in isolation. Gastrointestinal involvement is uncommon, and diagnosis is often challenging due to non-specific imaging features and clinical presentation. We report the case of a 75-year-old patient with newly diagnosed AML who was found to have synchronous cecal wall thickening and an adjacent hypodense lesion on abdominal computed tomography (CT). Due to an impending obstruction, surgery was performed, and the patient underwent ileocecectomy with primary anastomosis. Histopathology revealed extensive infiltration of the intestinal wall by immature hematopoietic cells, immunopositive for leukocyte common antigen (LCA), myeloperoxidase (MPO), and c-Kit, consistent with synchronous MS. Postoperatively, the patient was managed with standard AML therapy (chemotherapy with cytarabine plus an anthracycline was initiated). MS is difficult to diagnose radiologically and may mimic other malignancies or inflammatory processes. Definitive diagnosis relies on histopathology and immunohistochemistry. No standardized treatment exists; AML-based chemotherapy remains the mainstay, with hematopoietic stem cell transplantation considered for treatment intensification. Surgical intervention is reserved for complications such as obstruction or perforation. This case underscores the rarity and diagnostic challenge of synchronous MS in AML. Early recognition requires high clinical suspicion, and diagnosis depends on pathology. Further studies are needed to guide optimal management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.